|
**Overview**: **Testosterone Total Free Profile****Introduction**: The Testosterone Total Free Profile is a diagnostic tool designed to assess testosterone levels using serum samples. Associated with conditions like hypogonadism and hormonal imbalances, these disorders present with fatigue, reduced libido, and severe complications if untreated, particularly in individuals with suspected hormonal disorders. Per the 2023 Endocrinology guidelines, the test employs endocrinology with immunoassay technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for hormone screening in clinical settings. This diagnostic falls under hormone screening and targets individuals with suspected testosterone imbalances, addressing the challenge of accurate testosterone assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Testo Total Free Pfl.**FDA Status**: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1980s by endocrinology labs, this test advanced testosterone screening.**Purpose**: The test screens for 2 parameters including total testosterone to guide hormonal assessment, assess total and free testosterone levels, and inform treatment and prevention strategies.**Test Parameters**: 1. Total Testosterone, 2. Free Testosterone.**Pretest Condition**: No fasting required; patients should report fatigue, reduced libido, or recent hormonal symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on fatigue, reduced libido, prior hormonal reactions, or family history of hormonal disorders, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated hormonal disorders including bone loss, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent medication use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible hormonal disorders, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in endocrinology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: SHBG or imaging for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Endocrinology Guidelines 2023, Journal of Endocrinology 2024, Chemistry 2025. |
